Union Health Minister J. P. Nadda inaugurated the Laghu Udyog Bharati Pharma Conclave 2026 in New Delhi on Saturday, 25 July 2026, calling the pharmaceutical sector a 'key pillar of nation building' and reaffirming India's ambition to consolidate its standing as the 'Pharmacy of the World.'

Context

Addressing delegates at the conclave — an industry gathering focused on small-scale pharmaceutical units — Nadda framed the event as occurring at 'a pivotal moment in India's journey towards Viksit Bharat 2047,' the government's flagship vision to transform India into a developed economy by the centenary of independence. He highlighted four pillars the sector embodies: driving innovation, creating jobs, ensuring affordable healthcare, and strengthening global leadership.

The minister credited Prime Minister Narendra Modi's leadership for India's emergence as 'the world's largest supplier of generic medicines, a leading vaccine producer, and a trusted pharmaceutical exporter to over 200 countries.' The Laghu Udyog Bharati platform specifically represents micro, small and medium enterprises (MSMEs) in the manufacturing space, making the conclave a signal of the government's intent to integrate smaller units into the broader export-oriented pharma framework.

Policy Backdrop

India's pharmaceutical rise has been underpinned by a series of deliberate policy interventions since the Make in India programme launched in 2014. The Production Linked Incentive (PLI) scheme for pharmaceuticals, approved in 2021, was designed to boost domestic manufacturing capacity, incentivise innovation, and accelerate export growth by offering financial incentives tied to incremental sales.

The country's global health diplomacy credentials were bolstered by the Vaccine Maitri initiative in 2021, under which India supplied COVID-19 vaccines to over 100 countries, reinforcing its identity as a reliable supplier to the developing world. Successive policy cycles have sought to deepen self-reliance in active pharmaceutical ingredients (APIs) — a vulnerability exposed during the pandemic — while expanding the export footprint of finished formulations.

The emphasis on MSME pharma units at the Laghu Udyog Bharati conclave reflects a recognition that small-scale manufacturers form the backbone of India's generic medicine output and that their integration into quality-compliant, export-ready supply chains is essential to sustaining the country's global leadership claim.

Stakeholders and Impact

The conclave's primary audience — MSME pharmaceutical units — stands to benefit directly from any policy announcements or regulatory guidance that emerges from such platforms. Affordable generic medicines produced by these units serve hundreds of millions of domestic consumers and are a critical source of low-cost drugs for health systems across Africa, Southeast Asia, and Latin America.

For workers, the sector represents a significant employment base; the government has consistently cited job creation as a central dividend of pharma sector growth. Global health agencies and governments that depend on Indian generics for essential medicine procurement also have a direct stake in the policy environment shaping this industry.

What's Next

Industry observers will watch for follow-through in the form of PLI scheme expansions, regulatory streamlining for MSME units, or fresh export promotion measures that may be announced in forthcoming parliamentary sessions or the annual pharma policy review. Nadda's dual portfolio — overseeing both health policy and the chemicals and fertilizers ministry, which regulates pharmaceuticals — positions him as the central figure in translating the conclave's momentum into actionable reform. India's ability to maintain its 'Pharmacy of the World' identity will increasingly depend on whether smaller manufacturers can meet rising global quality standards while keeping costs competitive.